185 results on '"Tibau, Ariadna"'
Search Results
2. Treatment with anticancer drugs for advanced pancreatic cancer: a systematic review
3. Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review
4. Comprehensive clinical characteristics and ctDNA mutational profile analysis of endocrine resistance/sensitivity to adjuvant ET therapy in luminal breast cancer from the GEICAM/2014-03_RegistEM registry.
5. Global cooperation and early access—clinical outcomes matter
6. Association between control group therapy and magnitude of clinical benefit of cancer drugs
7. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study.
8. Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy
9. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
10. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.
11. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis
12. Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals
13. Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients
14. Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
15. Supplementary Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
16. Abstract P4-07-38: Real-world data of Advanced Breast Cancer (ABC) patients with HER2-positivity before the second-line therapy: data from the observational study GEICAM/2014-03 (RegistEM)
17. Abstract P4-07-30: Features and survival outcomes of HER2-low patients from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)
18. Abstract P4-07-45: Treatment strategies for advanced triple negative breast cancer patients as per routine clinical practice: analysis from the observational study GEICAM/2014-03 (RegistEM)
19. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
20. sj-docx-1-tam-10.1177_17588359221148921 – Supplemental material for Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
21. Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs
22. Association between control group therapy and magnitude of clinical benefit of cancer drugs.
23. Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer
24. Reforms to accelerated approval of new medicines: long overdue
25. Clinical benefit of cancer drugs approved in Switzerland 2010–2019
26. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.
27. Reforms to accelerated approval of new medicines: long overdue
28. Low-density lipoprotein receptor–related protein 1 is associated with proliferation and invasiveness in Her-2/ neu and triple-negative breast carcinomas
29. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
30. The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis
31. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration
32. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe
33. Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer
34. Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations
35. Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years.
36. Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period
37. Abstract PS7-35: Geicam/2014-03 (registem): A prospective registry of advanced breast cancer: A subset of triple negative breast cancer patients with her2 low expression
38. Abstract PS7-08: Characteristics of HR+/HER2- patients with recurrent disease from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)
39. Abstract PS7-25: Geicam/2014-03 (RegisTEM): A prospective registry of unresectable locally advanced or metastatic breast cancer: Characteristics of a subset of patients with triple negative subtype
40. Abstract PS7-24: Characteristics of HR+/HER2- patients with recurrent disease by HER2 expression from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)
41. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis
42. National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study
43. MP57-09 TIME TO APPROVAL OF NOVEL CANCER MEDICINES GRANTED ACCELERATED APPROVAL AND IMPLICATIONS FOR REFORM OF THE ACCELERATED APPROVAL PATHWAY.
44. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
45. Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period.
46. Value of multigene panel retesting of families with BRCA1/2 mutation-negative hereditary breast and ovarian cancer (HBOC).
47. Abstract PD10-06: Clinical benefit of breast cancer drugs approved by the United States Food and Drug Administration
48. Association Between Data Sources and US Food and Drug Administration Drug Safety Communications
49. Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment
50. Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.